Sometimes in biotech, your rival's bad news is your good news. That's the story Monday for Ocular Therapeutix (OCUL), whose shares jumped more than 6% after a competitor stumbled in a key clinical trial.

The competitor is EyePoint (EYPT), which released topline results from its pivotal Phase 3 LUGANO trial. The study tested Duravyu, its treatment for wet age-related macular degeneration (wet AMD). While the trial showed significant clinical progress on key secondary endpoints, it missed its primary visual acuity endpoint. EyePoint blamed a confounding patient subgroup for the miss.

For Ocular, the setback for a rival is a chance to shine. The company is developing Axpaxli (also known as OTX-TKI) for wet AMD and diabetic retinal disease. The treatment combines a bioresorbable intravitreal hydrogel with axitinib, a small-molecule, multi-target tyrosine kinase inhibitor.

Ocular is planning to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2026. The application will be supported by SOL-1 efficacy and safety data, along with an interim SOL-R safety analysis of patients reaching Week 52 in the fourth quarter, plus confirmatory evidence.

In its latest quarterly earnings release, Peter Kaiser, Chief Development Officer of Ocular Therapeutix, touted the strength of the SOL-1 data. "SOL-1 is the first and only successful superiority trial of a novel agent against an approved anti-VEGF therapy since the class emerged two decades ago," he said.

Analysts at William Blair weighed in on Monday, offering a nuanced take on the EyePoint results. "Given the totality of the data here, we expect Duravyu would likely be able to be filed on a clean positive readout from LUCIA, though we see greater regulatory risk," they wrote.

Analyst Lachlan Hanbury-Brown said the results provide additional validation for the TKI class, but he cautioned that differences in trial design make a direct comparison between Duravyu and Axpaxli difficult.

Still, William Blair sees the bigger picture in Ocular's favor. The positive topline and additional SOL-1 results support Axpaxli's profile as a durable and effective treatment for nAMD, and the firm sees potential in other vascular retinal diseases as well.

The firm also said the results reduce risk around the ongoing SOL-R study, which is expected to read out in the first quarter of 2028, as well as Axpaxli's potential approval.

At the time of publication Monday, Ocular Therapeutix shares were up 6.32% at $10.81, according to market data.